The DOI matches its Crossref record; 43 of the 43 references it cites were found in a registry or an index.
Discovery of a Mutant-Selective Covalent Inhibitor of EGFR that Overcomes T790M-Mediated Resistance in NSCLC
Open accessPublished version of a preprint
Abstract
Patients with non–small cell lung cancer (NSCLC) with activating EGF receptor (EGFR) mutations initially respond to first-generation reversible EGFR tyrosine kinase inhibitors. However, clinical efficacy is limited by acquired resistance, frequently driven by the EGFRT790M mutation. CO-1686 is a novel, irreversible, and orally delivered kinase inhibitor that specifically targets the mutant forms of EGFR, including T790M, while exhibiting minimal activity toward the wild-type (WT) receptor. Oral administration of CO-1686 as single agent induces tumor regression in EGFR-mutated NSCLC tumor xenograft and transgenic models. Minimal activity of CO-1686 against the WT EGFR receptor was observed. In NSCLC cells with acquired resistance to CO-1686 in vitro, there was no evidence of additional mutations or amplification of the EGFR gene, but resistant cells exhibited signs of epithelial–mesenchymal transition and demonstrated increased sensitivity to AKT inhibitors. These results suggest that CO-1686 may offer a novel therapeutic option for patients with mutant EGFR NSCLC. Significance: We report the preclinical development of a novel covalent inhibitor, CO-1686, that irreversibly and selectively inhibits mutant EGFR, in particular the T790M drug-resistance mutation, in NSCLC models. CO-1686 is the first drug of its class in clinical development for the treatment of T790M-positive NSCLC, potentially offering potent inhibition of mutant EGFR while avoiding the on-target toxicity observed with inhibition of the WT EGFR. Cancer Discov; 3(12); 1404–15. ©2013 AACR. This article is highlighted in the In This Issue feature, p. 1317
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Rociletinib (XegafriTM, CO-1686) (65), developed by Clovis Oncology, is a specific mutant agent for the treatment of NSCLC, belonging to the third-generation EGFR TKIs.190,191”
From Recent advances in targeting the “undruggable” proteins: from drug discovery to clinical trials (2023) · cites this paper as [190]
In the citing paper
“Additionally, covalent inhibitors can exhibit high selectivity for proteins with non-conserved residues between variant forms or protein family members [41].”
From The design and development of covalent protein-protein interaction inhibitors for cancer treatment (2020) · cites this paper as [41]
In the citing paper
“AZD9291 has a distinct chemical structure from the other third-generation TKIs, WZ4002 (34) and CO-1686 (35).”
From AZD9291, an Irreversible EGFR TKI, Overcomes T790M-Mediated Resistance to EGFR Inhibitors in Lung Cancer (2014) · cites this paper as [35]
In the citing paper
“Indeed, pre-clinical reports have suggested that “third generation” agents can induce switching to multiple signaling mechanisms that bypass EGFR dependency such as ERK and AKT pathways (35, 61, 62).”
From AZD9291, an Irreversible EGFR TKI, Overcomes T790M-Mediated Resistance to EGFR Inhibitors in Lung Cancer (2014) · cites this paper as [35]
In the citing paper
“Preclinical studies have confirmed that rociletinib has minimal activity against wild-type EGFR.7”
From Rociletinib in EGFR-Mutated Non–Small-Cell Lung Cancer (2015) · cites this paper as [7]
In the citing paper
“Rociletinib (CO-1686) is an EGFR inhibitor active in preclinical models of EGFR-mutated NSCLC with or without T790M.”
From Rociletinib in EGFR-Mutated Non–Small-Cell Lung Cancer (2015) · cites this paper as [7]
In the citing paper
“In xenograft models with EGFR-activating mutations alone or combined with T790M resistance mutations, rociletinib resulted in durable tumor shrinkage, 7 which was most marked when plasma concentrations were maintained at more than 200 ng per milliliter across the dosing interval.”
From Rociletinib in EGFR-Mutated Non–Small-Cell Lung Cancer (2015) · cites this paper as [7]
In the citing paper
“Rociletinib (CO-1686; Clovis Oncology) is a small-molecule, orally available, mutant-selective covalent inhibitor of commonly mutated forms of EGFR, including exon 19 deletions, L858R, and T790M, but not exon 20 insertions.”
From Rociletinib in EGFR-Mutated Non–Small-Cell Lung Cancer (2015) · cites this paper as [7]
In the citing paper
“Indeed, it seems that EGFR monoclonal antibodies 60 and EGFR WT kinase sparing covalent T790M selective TKIs 61 are ineffective in typical EGFR exon 20 insertion mutants.”
From Structural, Biochemical, and Clinical Characterization of Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertion Mutations in Lung Cancer (2013) · cites this paper as [61]
In the citing paper
“Cysteine 797 is the site of covalent binding for all three of these agents (14–16).”
From EGFR Mutations and Resistance to Irreversible Pyrimidine-Based EGFR Inhibitors (2015) · cites this paper as [15]
In the citing paper
“They are not only more potent on EGFR T790M, but also selectively inhibit mutant over WT EGFR and hence should lead to increased clinical efficacy and less toxicity compared with afatinib (14–16).”
From EGFR Mutations and Resistance to Irreversible Pyrimidine-Based EGFR Inhibitors (2015) · cites this paper as [15]
In the citing paper
“These include the development of mutant selective EGFR kinase inhibitors, including WZ4002, CO-1686 and AZD9291, which to date have demonstrated encouraging efficacy in both preclinical models and in EGFR mutant NSCLC patients with EGFR T790M mediated drug resistance (14–18).”
From EGFR Mutations and Resistance to Irreversible Pyrimidine-Based EGFR Inhibitors (2015) · cites this paper as [15]
In the citing paper
“CO-1686 is structurally more closely related to WZ4002 than to AZD9291 and in all of the models tested CO-1686 is very similar in vitro to WZ4002 (14–16).”
From EGFR Mutations and Resistance to Irreversible Pyrimidine-Based EGFR Inhibitors (2015) · cites this paper as [15]
In the citing paper
“Additional pre-clinical studies have also identified activation of MAPK signaling and IGF1R signaling as well as epithelial to mesenchymal (EMT) transition as potential resistance mechanisms to WZ4002 and CO-1686 (15, 19, 20).”
From EGFR Mutations and Resistance to Irreversible Pyrimidine-Based EGFR Inhibitors (2015) · cites this paper as [15]
In the citing paper
“In vitro and in vivo studies demonstrated that Rociletinib irreversibly and selectively inhibits mutant EGFR, including T790M mutation, with minimal activity against wild type EGFR, suggesting that drug tolerability to this agent may be superior to first and second generation EGFR inhibitors”
From A decade of EGFR inhibition in EGFR-mutated non small cell lung cancer (NSCLC): Old successes and future perspectives (2015) · cites this paper as [85]
In the citing paper
“Both 2G and 3G EGFR‐TKI are irreversible small‐molecule inhibitors that covalently bind to EGFR kinase by targeting the cysteine‐797 residue, located in the ATP binding pocket, and 3G EGFR‐TKI are considered to be more specific for EGFR sensitizing mutations than 2G EGFR‐TKI.12, 13, 14”
In the citing paper
“Osimertinib and rociletinib are 3rd generation EGFR-TKIs, both of which are reported to be effective in lung cancer cells harboring EGFR T790M in preclinical models [30, 32].”
In the citing paper
“A third generation of EGFR inhibitors followed afatinib; these covalent inhibitors selectively target the T790M mutant over wild-type EGFR, and include WZ4002 (Dana–Farber Cancer Institute)43, osimertinib44,45 and rociletinib (Clovis Oncology; CO-1686)46 (Fig. 2c).”
From Advances in covalent drug discovery (2022) · cites this paper as [46]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Gefitinib or Carboplatin–Paclitaxel in Pulmonary Adenocarcinoma
Mok, T. S., Wu, Y.-L., Thongprasert, S., Yang, C.-H., Chu, D.-T., Saijo, N., Sunpaweravong, P., Han, B., Margono, B., Ichinose, Y., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0810699 · Cited by 8,261 · cited 1×
“Patients with the most common EGFR mutations (L858R mutation in exon 21 and delE746-A750 deletions in exon 19) typically have good responses to therapy with first-generation reversible EGFR tyrosine kinase inhibitors (TKIs), such as erlotinib or gefitinib (3-5).”
Rosell, R., Carcereny, E., Gervais, R., Vergnenegre, A., Massuti, B., Felip, E., Palmero, R., Garcia-Gomez, R., Pallares, C., Sanchez, J. M., et al. (2012) · The Lancet Oncology · doi:10.1016/s1470-2045(11)70393-x · Cited by 5,489
MET Amplification Leads to Gefitinib Resistance in Lung Cancer by Activating ERBB3 Signaling
Engelman, J. A., Zejnullahu, K., Mitsudomi, T., Song, Y., Hyland, C., Park, J. O., Lindeman, N., Gale, C.-M., Zhao, X., Christensen, J., et al. (2007) · Science · doi:10.1126/science.1141478 · Cited by 4,496
Pao, W., Miller, V., Zakowski, M., Doherty, J., Politi, K., Sarkaria, I., Singh, B., Heelan, R., Rusch, V., Fulton, L., et al. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0405220101 · Cited by 4,338
Self-citationEGFR Mutation and Resistance of Non–Small-Cell Lung Cancer to Gefitinib
Kobayashi, S., Boggon, T. J., Dayaram, T., Jänne, P. A., Kocher, O., Meyerson, M., Johnson, B. E., Eck, M. J., Tenen, D. G., & Halmos, B. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa044238 · Cited by 3,964
Pao, W., Miller, V. A., Politi, K. A., Riely, G. J., Somwar, R., Zakowski, M. F., Kris, M. G., & Varmus, H. (2005) · PLoS Medicine · doi:10.1371/journal.pmed.0020073 · Cited by 3,527 · cited 2×
“second site EGFR point mutation that results in the substitution of threonine with methionine at amino acid position 790 (T790M;(7-10)).”
BackgroundSelf-citationGenotypic and Histological Evolution of Lung Cancers Acquiring Resistance to EGFR Inhibitors
Sequist, L. V., Waltman, B. A., Dias-Santagata, D., Digumarthy, S., Turke, A. B., Fidias, P., Bergethon, K., Shaw, A. T., Gettinger, S., Cosper, A. K., et al. (2011) · Science Translational Medicine · doi:10.1126/scitranslmed.3002003 · Cited by 3,499
Epidermal growth factor receptor mutations in lung cancer
Sharma, S. V., Bell, D. W., Settleman, J., & Haber, D. A. (2007) · Nature Reviews Cancer · doi:10.1038/nrc2088 · Cited by 3,170
A quantitative analysis of kinase inhibitor selectivity
Karaman, M. W., Herrgard, S., Treiber, D. K., Gallant, P., Atteridge, C. E., Campbell, B. T., Chan, K. W., Ciceri, P., Davis, M. I., Edeen, P. T., et al. (2008) · Nature Biotechnology · doi:10.1038/nbt1358 · Cited by 2,466
Yu, H. A., Arcila, M. E., Rekhtman, N., Sima, C. S., Zakowski, M. F., Pao, W., Kris, M. G., Miller, V. A., Ladanyi, M., & Riely, G. J. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-2246 · Cited by 2,454
Self-citation
Cited by
Sorted by citations
Items 501–600 of 686
Wu, Y. (2014) · Medicinal Chemistry · doi:10.4172/2161-0444.s1-007 · Cited by 5
Zhang, Z., Zou, J., Yu, L., Luo, J., Li, Y., Tu, Z., Ren, X., Wei, H., Song, L., Lu, X., et al. (2018) · Cancer Medicine · doi:10.1002/cam4.1392 · Cited by 5
Akher, F. B., Farrokhzadeh, A., Ravenscroft, N., & Kuttel, M. M. (2019) · Biochemistry · doi:10.1021/acs.biochem.9b00710 · Cited by 5
Ruslin, R., Amelia, R., Yamin, Y., Megantara, S., Wu, C. F., & Arba, M. (2019) · Journal of Applied Pharmaceutical Science · doi:10.7324/japs.2019.90113 · Cited by 5
Gong, S., Hu, X., Chen, S., Sun, B., Wu, J., & Li, N. (2022) · Medicinal Research Reviews · doi:10.1002/med.21889 · Cited by 5
Cao, Y., Lu, X., Fu, L., Shi, T., Zhang, C., Zeng, L., Zhang, J., Shao, J., Xi, J., Pan, Z., et al. (2023) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2023.106494 · Cited by 5
Jang, J., Son, J., Park, E., Kosaka, T., Saxon, J. A., Clercq, D. J. H. D., Choi, H. G., Tanizaki, J., Eck, M. J., Janne, P. A., et al. (2018) · Angewandte Chemie · doi:10.1002/ange.201805187 · Cited by 5
Hu, X., Wang, D., Tong, Y., Tong, L., Wang, X., Zhu, L., Xie, H., Li, S., Yang, Y., & Xu, Y. F. (2017) · Frontiers in Chemistry · doi:10.3389/fchem.2017.00101 · Cited by 5
Walker, J. C., Yan, K., & Derda, R. (2026) · Biochemistry · doi:10.1021/acs.biochem.5c00646 · Cited by 4
Fan, F., Zhou, M., Ye, X., Mo, Z., Ma, Y., Luo, L., Liang, X., Liu, H., Weng, Y., Lin, M., et al. (2020) · Translational Oncology · doi:10.1016/j.tranon.2020.100961 · Cited by 4
Implementation of modern therapy approaches and research for non‐small cell lung cancer in J apan
Nakanishi, Y. (2015) · Respirology · doi:10.1111/resp.12460 · Cited by 4
A Novel and Efficient Synthesis of Anti-Cancer Agent, Mereletinib
Liu, H., Lv, Y.-F., Li, Y., Cai, J., Chen, J., Yu, Q., & Ji, M. (2015) · Journal of Chemical Research · doi:10.3184/174751915x14320297505570 · Cited by 4
Guide for Selection of Relevant Cell Lines During the Evaluation of new Anti-Cancer Compounds
Ruiz-Moreno, A. J., Torres-Barrera, P., Velázquez-Paniagua, M., Dömling, A. S. S., & Velasco-Velázquez, M. A. (2018) · Anti-Cancer Agents in Medicinal Chemistry · doi:10.2174/1871520618666180220120544 · Cited by 5
Management of Toxicities of Targeted Therapies
Yang, J. C., Lin, C.-C., & Chu, C. (2018) · Elsevier eBooks · doi:10.1016/b978-0-323-52357-8.00049-4 · Cited by 4
Patel, H., Pawara, R. H., & Surana, S. J. (2019) · Elsevier eBooks · doi:10.1016/b978-0-08-102661-8.00001-9 · Cited by 4
Brosseau, S., Viala, M., Varga, A., Planchard, D., Besse, B., & Soria, J. (2015) · Bulletin du Cancer · doi:10.1016/j.bulcan.2015.05.001 · Cited by 5
Qin, M., Wang, L., Yan, S., Ma, J.-J., Tian, Y., Zhao, Y., & Gong, P. (2016) · Chinese Chemical Letters · doi:10.1016/j.cclet.2016.11.030 · Cited by 5
Parsons, A. T., Kubryk, M., Hedley, S. J., Thiel, O. R., Bauer, D., Potter, M. S., & Lin, Z. (2018) · Organic Process Research & Development · doi:10.1021/acs.oprd.8b00080 · Cited by 4
Approved and Clinical Trial Third-Generation EGFR Inhibitors
Patel, H., Pawara, R. H., & Surana, S. J. (2019) · Elsevier eBooks · doi:10.1016/b978-0-08-102661-8.00002-0 · Cited by 4
Oashi, A., Yasuda, H., Kobayashi, K., Tani, T., Hamamoto, J., Masuzawa, K., Manabe, T., Terai, H., Ikemura, S., Kawada, I., et al. (2019) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-18-1036 · Cited by 4
Dai, H., Chao, G., Si, X., Yutong, Z., Zhengjie, W., Limin, L., Tao, W., Luye, Z., Yang, Z., Qin, Y., et al. (2022) · Russian Journal of Bioorganic Chemistry · doi:10.1134/s1068162022050090 · Cited by 4
Attwa, M. W., Abdelhameed, A. S., & Kadi, A. A. (2021) · Drug Design Development and Therapy · doi:10.2147/dddt.s321330 · Cited by 4
Immunotherapy and Targeted Therapies in the Treatment of Non-small Cell Lung Cancer
Nguyen‐Ngoc, T., Reck, M., Tan, D. S. W., & Peters, S. (2017) · European Oncology & Haematology · doi:10.17925/eoh.2017.13.01.35 · Cited by 4
The Role of Structural Biology in Kinase Inhibitor Drug Discovery Success
Angiolini, M. (2020) · Wiley eBooks · doi:10.1002/9781118681121.ch16 · Cited by 4
Jamal‐Hanjani, M., & Lee, S. M. (2015) · Lung Cancer Management · doi:10.2217/lmt.15.11 · Cited by 3
Lee, J. Y., Jeong, B., Jung, H. S., Kang, T., Park, Y., Rho, J. K., Park, S., & Lee, M. (2024) · Small Science · doi:10.1002/smsc.202400101 · Cited by 3
Bajaj, T., Mosavati, B., Zhang, L. H., Parsa, M. S., Wang, H., Kerek, E. M., Liang, X., Dakhili, S. A. T., Wehri, E., Guo, S., et al. (2025) · RSC Advances · doi:10.1039/d4ra06955b · Cited by 3
Ramı́rez, J., House, L. K., & Ratain, M. J. (2021) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.14848 · Cited by 3
Shvetsov, A. B., & Semenov, A. (2024) · Russian Journal of Bioorganic Chemistry · doi:10.1134/s1068162024060347 · Cited by 3
Strategic Incorporation of Fluorine for Drug Discovery and Development
Honda, T., & Ojima, I. (2017) · Elsevier eBooks · doi:10.1016/b978-0-12-803740-9.00017-2 · Cited by 3
Limin, L., Wang, Z., Xiujuan, L., Chao, G., Dai, H., Wang, T., Na, L., Heyi, Y., Yang, Z., Zhang, L., et al. (2021) · Russian Journal of Bioorganic Chemistry · doi:10.1134/s1068162021060157 · Cited by 3
Self-citationLi, Y., Yu, Q.-L., Li, T.-F., Xiao, Y.-N., Zhang, L., Zhang, Q., Ren, C., & Xie, H. (2021) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2021.174297 · Cited by 3
RECENT ADVANCES ON PYRIMIDINE DERIVATIVES AS ANTICANCER AGENTS.
Mahdy, H. A., Elnagar, H., & Sakr, H. M. (2023) · Al-Azhar Journal of Pharmaceutical Sciences/Al-Azhar Journal of Pharmaceutical Sciences · doi:10.21608/ajps.2023.311246 · Cited by 3
Kubo, E., Yamamoto, N., Nokihara, H., Fujiwara, Y., Horinouchi, H., Kanda, S., Goto, Y., & Ohe, Y. (2016) · Molecular and Clinical Oncology · doi:10.3892/mco.2016.1076 · Cited by 3
Upadhyay, S. K., Rai, R. C., Gehtori, R., Paliwal, A., Gautam, P., & Joshi, P. (2017) · Springer eBooks · doi:10.1007/978-3-319-48683-3_20 · Cited by 4
Allosteric Inhibition of the Epidermal Growth Factor Receptor
Sinclair, J. K.-L., Robertson, W. E., Mozumdar, D., Quach, K., & Schepartz, A. (2021) · Biochemistry · doi:10.1021/acs.biochem.0c00978 · Cited by 3
Zhang, Y., Zhang, L., Wang, J., Liu, L., Wang, T., Li, N., Wang, Z., Liu, X., Chen, Y., Zhao, D., et al. (2021) · Chinese Journal of Organic Chemistry · doi:10.6023/cjoc202007067 · Cited by 3
Self-citationHögnäsbacka, A., Poot, A. J., Kooijman, E. J. M., Schuit, R. C., Schreurs, M., Verlaan, M., van den Hoek, J., Heideman, D. A. M., Beaino, W., van Dongen, G. A. M. S., et al. (2023) · Nuclear Medicine and Biology · doi:10.1016/j.nucmedbio.2023.108349 · Cited by 3
Lead compound bearing caffeic scaffold induces EGFR suppression in solid tumor cancer cells
Mudjupa, C., Abdelhamed, S., Refaat, A., Yokoyama, S., Saiki, I., & Vajragupta, O. (2015) · Journal of Applied Biomedicine · doi:10.1016/j.jab.2015.05.001 · Cited by 3
Coiled coil control of growth factor and inhibitor-dependent EGFR trafficking and degradationPreprint
Mozumdar, D., Chang, S. H.-H., Quach, K., Doerner, A. E., & Schepartz, A. (2020) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2020.12.10.419739 · Cited by 3
Gomha, S. M., Al‐Hussain, S. A., Farag, B., Nayl, A. A., Hussein, W. M., Sayed, A. R., & Zaki, M. E. A. (2025) · ChemistryOpen · doi:10.1002/open.202500555 · Cited by 2
Sivam, J., Daker, M., Marzuki, M., Lawal, A. Y., Leong, S. W., Sofian, Z. M., Noor, S. M., Sahudin, M. A., Ariffin, A., Sinniah, A., et al. (2026) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2026.109702 · Cited by 2
Update on NSCLC tissue acquisition, processing, and profiling in the molecular age
Conterato, A. J., Belanger, A. R., Yarmus, L. B., & Akulian, J. (2017) · Hematology & Medical Oncology · doi:10.15761/hmo.1000121 · Cited by 2
Dynamics of Acquired Resistance to Nivolumab Therapies Varies From Administration Strategies
Ji, J., Wu, H., Feng, X., Liu, X., Huang, C., Zheng, S., Jianjun, Z., & Liao, J. (2021) · Clinical Therapeutics · doi:10.1016/j.clinthera.2021.10.004 · Cited by 2
Anticancer drugs acting on signaling pathways, part 1: Tyrosine kinase inhibitors
Avendaño, C., & Menéndez, J. C. (2023) · Elsevier eBooks · doi:10.1016/b978-0-12-818549-0.00018-2 · Cited by 2
Huang, K., Huo, B., Li, D., Xue, J., & Chen, J. (2020) · ChemMedChem · doi:10.1002/cmdc.202000036 · Cited by 2
Ni, L., & Nie, L. (2018) · Europe PMC (PubMed Central) · doi:10.3779/j.issn.1009-3419.2018.02.02 · Cited by 2
Lin, Y.-W., Kao, H., Chen, W.-T., Kao, C.-F., Wu, J., Chen, Y.-T., & Lee, Y. (2023) · JCI Insight · doi:10.1172/jci.insight.171257 · Cited by 3
Targeted Therapy und Precision Medicine
Heigener, D. F., Horn, M., & Reck, M. (2016) · Der Internist · doi:10.1007/s00108-016-0121-z · Cited by 2
Medicinal Chemistry Case History: Osimertinib (AZD9291)
Ward, R. A., & Finlay, M. R. V. (2016) · Elsevier eBooks · doi:10.1016/b978-0-12-409547-2.12448-5 · Cited by 2
Cancer Clonal Evolution and Intra-tumor Heterogeneity
Fanale, D., Iovanna, J., Giordano, A., Rolfo, C. D., & Russo, A. D. (2017) · Current clinical pathology · doi:10.1007/978-3-319-55661-1_3 · Cited by 2
Manzo, A., Montanino, A., Costanzo, R., Sandomenico, C., Palumbo, G., Schettino, C., Daniele, G., Morabito, A., Perrone, F., & Piccirillo, M. C. (2018) · Elsevier eBooks · doi:10.1016/b978-0-12-811785-9.00033-8 · Cited by 2
Gürsoy, P., Çakar, B., Ön, S., Göker, E., & Nart, D. (2022) · Turkish Thoracic Journal · doi:10.5152/turkthoracj.2022.21270 · Cited by 2
Kulikov, K. G., Koshlan, T., & Golovitsky, A. P. (2023) · Biophysical Reviews and Letters · doi:10.1142/s1793048023500017 · Cited by 2
Du, L., Suo, S., Zhang, H., Jia, H., Liu, K. J., Zhang, X. J., & Liu, Y. (2016) · Nanotechnology · doi:10.1088/0957-4484/27/44/445101 · Cited by 2
Radiolabeled EGFR Tyrosine Kinase for the Detection of Dual Mutations EGFR L858R/T790M in NSCLC
(2023) · Biointerface Research in Applied Chemistry · doi:10.33263/briac135.500 · Cited by 2
Xie, J., Xu, W., Deng, H., Wu, X., & Zhu, J. (2026) · Frontiers in Bioengineering and Biotechnology · doi:10.3389/fbioe.2026.1741512 · Cited by 1
Therapy-induced cholesterol biosynthesis drives lung cancer dormancy and drug resistance
Zhao, Y., Zhou, Y., Pan, L., Tian, G. G., Huang, H., Tang, S., Lu, M., Zhou, Z., Zhang, P., Chen, L., et al. (2026) · Journal of Clinical Investigation · doi:10.1172/jci191735 · Cited by 1
Chen, Y., Liu, Q.-P., Yang, S.-J., Ding, J., Lu, X.-Y., & Xie, H. (2026) · Acta Pharmacologica Sinica · doi:10.1038/s41401-026-01855-0 · Cited by 1
Design, Synthesis, and Evaluation of Selective Ubiquitin-Specific Protease 11 (USP11) Inhibitors
Hassan, M. A., Dekker, L. V., Stocks, M. J., & Dreveny, I. (2025) · ACS Omega · doi:10.1021/acsomega.5c08248 · Cited by 1
Insights and perspectives into the etiology of TKI-induced cardiotoxicity
Xu, V., Ahmed, B., Boleslav, B., Mager, D., Sparreboom, A., Sprowl, J. A., & Huang, K. M. (2026) · ASPET Discovery · doi:10.1016/j.aspetd.2026.100025 · Cited by 1
Kollár, L., Mihalovits, L. M., Bajusz, D., Knez, D., Simon, J., Balcomb, B. H., Fearon, D., Gobec, S., & Keserű, G. M. (2026) · ChemMedChem · doi:10.1002/cmdc.202501108 · Cited by 1
[TKI Resistance for T790M Mutation].
Wang, H., Guo, R., & Zhang, L. (2015) · Europe PMC (PubMed Central) · doi:10.3779/j.issn.1009-3419.2015.04.10 · Cited by 1
Seton-Rogers, S. E. (2013) · Nature reviews. Cancer · doi:10.1038/nrc3624 · Cited by 1
Overcoming Resistance to EGF Receptor Tyrosine Kinase Inhibitors in EGFR -mutated NSCLC
Saad, S., Huang, K., & Halmos, B. (2014) · Lung Cancer Management · doi:10.2217/lmt.14.35 · Cited by 1
Monitoring Conformational Changes in the Receptor Tyrosine Kinase EGFR
Becker, C., Öcal, S., Nguyen, H. D., Phan, T. T. P., Keul, M., Simard, J. R., & Rauh, D. (2016) · ChemBioChem · doi:10.1002/cbic.201600115 · Cited by 1
(2018) · Journal of Cellular Biochemistry · doi:10.1002/jcb.27811 · Cited by 1
RetractedBourdeanu, L., Liu, E. Y., Brint, S., & Langdon, D. E. (2017) · Resistance to targeted anti-cancer therapeutics · doi:10.1007/978-3-319-70142-4_4 · Cited by 1
EGFRp4 Peptides: A Novel Strategy for Epidermal Growth Factor Receptor (EGFR) Inhibitor
Jiwacharoenchai, N., Kiriwan, D., Chang, S.-Y., Weng, C. C., Li, Y., Tabtimmai, L., & Choowongkomon, K. (2025) · ACS Omega · doi:10.1021/acsomega.5c01684 · Cited by 1
Safety and efficacy of targeted agents monotherapy in advanced NSCLC
Zhang, Q., & Wu, Y.-L. L. C. (2015) · Expert Review of Clinical Pharmacology · doi:10.1586/17512433.2016.1101340 · Cited by 1
Niu, A., Wang, Y., Yang, Y., Wei, J., Ding, J., Chen, Y., Tong, L., & Xie, H. (2018) · Letters in Drug Design & Discovery · doi:10.2174/1570180815666180523090558 · Cited by 1
Kubo, N., Harada, T., Shiraishi, Y., Nosaki, K., Nakagaki, N., Takeshita, M., Ouchi, H., Iwama, E., Tanaka, K., Okamoto, I., et al. (2019) · Anticancer Research · doi:10.21873/anticanres.13162 · Cited by 1
Coiled coil control of diverse EGFR functions
Mozumdar, D., Quach, K., Doerner, A. E., & Schepartz, A. (2021) · The FASEB Journal · doi:10.1096/fasebj.2021.35.s1.03155 · Cited by 1
Stressing the need to overcome EGFR tyrosine kinase inhibitor resistance
Toulabi, L., & Ryan, B. M. (2018) · Translational Lung Cancer Research · doi:10.21037/tlcr.2018.03.05 · Cited by 1
Cretella, D. (2015) · DSpaceUnipr (University of Parma)
Predictive biomarkers in diffuse gliomas and non-small cell lung cancer
Merkkiniemi, K. (2015) · Työväentutkimus Vuosikirja
Adjuvant Epithelial Growth Factor Receptor Tyrosine Kinase Inhibitors in Lung Cancer
Davis, M. P., Velcheti, V., & Pennell, N. A. (2016) · CHEST Journal · doi:10.1016/j.chest.2016.01.032
Covalent Kinase Inhibitors for Cancer
Owens, T. D., & Lou, Y. C. (2016) · Elsevier eBooks · doi:10.1016/b978-0-12-409547-2.12399-6
Resistance of Lung Cancer to Kinase Inhibitors Specific to EGFR or ALK
Mancini, M., & Yarden, Y. (2018) · Resistance to targeted anti-cancer therapeutics · doi:10.1007/978-3-319-67932-7_2
Conclusion and Future Perspectives
Patel, H., Pawara, R. H., & Surana, S. J. (2019) · Elsevier eBooks · doi:10.1016/b978-0-08-102661-8.00007-x
Clinical Strategies for Developing Next-Generation Cancer Precision Medicines
See, C. G. (2019) · Springer eBooks · doi:10.1007/978-3-030-18375-2_7
Oncogenic drivers and immunotherapy: staying one step ahead of lung cancer
Lartigue, J. D. (2015) · The Journal of Community and Supportive Oncology · doi:10.12788/jcso.0146
Analysis to determine the effect of mutations on binding to small chemical molecules
Koshlan, T. V., & Kulikov, K. G. (2022) · Journal of Bioinformatics and Computational Biology · doi:10.1142/s0219720022400030
Kobayashi, K., & Kagamu, H. (2017) · Springer eBooks · doi:10.1007/978-981-10-2002-5_10
Current Approaches in the Development of Covalent Reversible EGFR Inhibitors
Patel, H., Pawara, R. H., & Surana, S. J. (2019) · Elsevier eBooks · doi:10.1016/b978-0-08-102661-8.00004-4
The Role of AXL Receptor Tyrosine Kinase in Cancer Cell Plasticity and Therapy Resistance
Lotsberg, M. L., Davidsen, K. T., Peters, S. D., Haaland, G. S., Rayford, A. J., Lorens, J. B., & Engelsen, A. S. T. (2022) · Springer eBooks · doi:10.1007/978-3-030-98950-7_18
Ahmad, I., Pawara, R. H., Pathan, A., & Patel, H. (2022) · Springer eBooks · doi:10.1007/978-981-19-0932-0_1
A computational study to reveal selpercatinib resistance to RET kinase double mutant V804M/Y806C
Zheng, G., Li, M.-Y., Zhang, J., Liu, W., Jiang, L., Liang, W., Wang, J., Shi, H., Kang, Z., & Zhou, B. (2022) · Chemical Papers · doi:10.1007/s11696-022-02479-4
Dayanc, B., Eris, S., & Şentürk, Ş. (2022) · Interdisciplinary cancer research · doi:10.1007/16833_2022_54
The development and implementation of EGFR inhibitors in advanced NSCLC
Neuwelt, A. J., & Camidge, D. R. (2023) · Elsevier eBooks · doi:10.1016/b978-0-12-822833-3.00007-3
In silico target specific design of potential quinazoline-based anti-NSCLC agents
Mohammadnejadi, E., & Razzaghi‐Asl, N. (2023) · Journal of Biomolecular Structure and Dynamics · doi:10.1080/07391102.2023.2183029
Zhang, X., Maity, T. K., ROSS, K. E., Qi, Y., Cultraro, C. M., Bahta, M., Pitts, S., Keswani, M., Gao, S., Nguyen, K. D. P., et al. (2023) · doi:10.1158/0008-5472.c.6513445.v1
Data from Functional Determinants of Cell Cycle Plasticity and Sensitivity to CDK4/6 Inhibition
Kumarasamy, V. M., Vail, P. J., Nambiar, R., Witkiewicz, A. K., & Knudsen, E. S. (2023) · doi:10.1158/0008-5472.c.6512736.v1
Drugs that modulate resistance to antitumor agents
Avendaño, C., & Menéndez, J. C. (2023) · Elsevier eBooks · doi:10.1016/b978-0-12-818549-0.00007-8
Targeting phospholipase C using synthetic inhibitors of EGFR signaling for cancer treatment
Krishnamoorthy, S., Periyasamy, L., Gnanagurusamy, J., Sabanayagam, R., Elango, H., Vishwanathan, M., & Muthusami, S. (2023) · Elsevier eBooks · doi:10.1016/b978-0-323-95699-4.00018-9
Potential of Heterocyclic Compounds as EGFR-TK Inhibitors in Cancer Therapy
Sarkate, A. P., Bhandari, S. V., Inamdar, P. R., Kuthe, P. V., & Padvi, K. S. (2023) · Springer eBooks · doi:10.1007/978-981-99-5281-6_7
The inhibitory effect of isavuconazole on almonertinib metabolism and its underlying mechanismPreprint
Chen, Z., Liu, Y., Xia, H., Yu, Y., & Xu, R.-A. (2024) · Research Square · doi:10.21203/rs.3.rs-4116071/v1
Evolving therapeutic landscape of EGFR-TKIs in NSCLC
Feng, C., Li, R., Li, X., & Xu, X. (2024) · Molecular & cellular biomechanics · doi:10.62617/mcb.v21.230
Shvetsov, A. B., & Semenov, A. V. (2024) · Биоорганическая химия · doi:10.31857/s0132342324060037
Metadata
- Authors
- Walter, A. O., Sjin, R. T. T., Haringsma, H. J., Ohashi, K., Sun, J., Lee, K., Dubrovskiy, A., Labenski, M., Zhu, Z., Wang, Z., Sheets, M., St Martin, T., Karp, R., van Kalken, D., Chaturvedi, P., Niu, D., Nacht, M., Petter, R. C., Westlin, W., Lin, K., Jaw-Tsai, S., Raponi, M., Van Dyke, T., Etter, J., Weaver, Z., Pao, W., Singh, J., Simmons, A. D., Harding, T. C., & Allen, A.
- Affiliations
- Vanderbilt University (US)
- Authors' Affiliations: 1Clovis Oncology Inc., San Francisco, California; 2Celgene Avilomics Research, Bedford, Massachusetts; 3Division of Hematology-Oncology, Department of Medicine, Vanderbilt University School of Medicine, Nashville, Tennessee; 4Mouse Cancer Genetics Program; and 5Center for Advanced Preclinical Research, Science Applications International Corporation-Frederick, Inc., National Cancer Institute, Frederick, Maryland
- Corresponding author
- Harding, Thomas C.
- ORCID
- Venue
- Cancer Discovery
- Published
- 2013-12-01
- Volume
- 3
- Issue
- 12
- Pages
- 1404-1415
- ISSN
- 2159-8274 (ISSN-L)
- 2159-8290
- PMC
- PMC4048995
- OpenAlex
- W2146418087
- Cited by
- 620
- References
- 43
- Citations by year
- 2026: 12 · 2025: 17 · 2024: 21 · 2023: 29 · 2022: 32 · 2021: 41 · 2020: 51 · 2019: 44 · 2018: 61 · 2017: 87 · 2016: 92 · 2015: 86 · 2014: 44 · 2013: 3
- FWCI
- 62.72
- Type
- journal article
- Language
- en
- Open access
- green
- kclpure.kcl.ac.uk
- Licence
- other-oa
- Locations
- Cancer Discovery (publishedVersion)
- PubMed (publishedVersion)
- Research Portal (King's College London) (publishedVersion, other-oa)
- PubMed Central (acceptedVersion)
- Funders
- National Institutes of Health (HHSN261200800001C)
- National Cancer Institute (P30 CA 68485, R01CA121210, P01CA129243, HHSN261200800001E), U54CA143798, P30CA068485)
- Topics
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
- Health Sciences › Medicine › Oncology › HER2/EGFR in Cancer Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer Mechanisms and Therapy
- Keywords
- EGFR tyrosine kinase inhibitors, T790M mutation, acquired drug resistance, non-small cell lung cancer, irreversible kinase inhibitors, epithelial-mesenchymal transition, AKT inhibitors, on-target toxicity
- MeSH terms
- Acrylamides, Administration, Oral, Animals, Antineoplastic Agents, Carcinoma, Non-Small-Cell Lung, Drug Screening Assays, Antitumor, Female, Humans, Lung Neoplasms, Mice, Inbred BALB C, Mice, Nude, Mice, Transgenic, Pyrimidines, Drug Resistance, Neoplasm, Xenograft Model Antitumor Assays, Cell Line, Tumor, Protein Kinase Inhibitors, Cell Proliferation, Mutant Proteins, Mice, HEK293 Cells, Epithelial-Mesenchymal Transition, Molecular Targeted Therapy, ErbB Receptors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
